Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSXNASDAQ:PIIINASDAQ:RNLXNASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$0.33-5.2%$0.50$0.17▼$2.04$47.71M1.182.32 million shs2.36 million shsPIIIP3 Health Partners$7.39+0.1%$8.57$7.00▼$33.73$53.10M0.9420,337 shs3,372 shsRNLXRenalytix$0.21$0.23$0.18▼$2.40$17.18M2.721.45 million shs934,496 shsSERASera Prognostics$1.64-0.6%$2.94$1.63▼$9.91$61.78M0.99137,444 shs278,215 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix-0.92%-13.14%-39.79%-57.79%-76.33%PIIIP3 Health Partners+1.79%-5.38%-16.59%-22.62%-72.63%RNLXRenalytix0.00%0.00%0.00%0.00%-51.85%SERASera Prognostics-1.79%-14.06%-45.00%-59.76%-80.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDSXBiodesix3.1623 of 5 stars4.42.00.00.02.22.50.6PIIIP3 Health Partners1.7101 of 5 stars3.32.00.00.02.00.80.6RNLXRenalytixN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.9173 of 5 stars0.02.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.80Moderate Buy$1.75437.63% UpsidePIIIP3 Health Partners 2.50Moderate Buy$16.25119.77% UpsideRNLXRenalytix 3.00Buy$3.001,348.58% UpsideSERASera Prognostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RNLX, SERA, PIII, and BDSX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025BDSXBiodesixScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.005/14/2025BDSXBiodesixLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $2.005/14/2025BDSXBiodesixCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.505/14/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $1.505/14/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform4/29/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.504/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.003/4/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$74.46M0.64N/AN/A$0.05 per share6.51PIIIP3 Health Partners$1.49B0.04$3.19 per share2.32$0.45 per share16.43RNLXRenalytix$2.29M7.50N/AN/A($0.10) per share-2.07SERASera Prognostics$115K537.25N/AN/A$2.21 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$52.15M-$0.29N/AN/AN/A-66.84%-275.79%-43.05%8/6/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)RNLXRenalytix-$33.46M-$0.39N/A∞N/A-1,461.60%N/A-281.40%N/ASERASera Prognostics-$36.24M-$0.94N/AN/AN/AN/A-51.73%-36.94%8/6/2025 (Estimated)Latest RNLX, SERA, PIII, and BDSX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million5/13/2025Q1 2025BDSXBiodesix-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 million3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 million3/3/2025Q4 2024BDSXBiodesix-$0.07-$0.06+$0.01-$0.06$19.92 million$20.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix1.303.403.40PIIIP3 Health Partners1.110.530.53RNLXRenalytixN/A0.530.53SERASera PrognosticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%PIIIP3 Health Partners7.75%RNLXRenalytix9.92%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix69.20%PIIIP3 Health Partners17.79%RNLXRenalytix18.30%SERASera Prognostics13.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix220146.56 million44.80 millionOptionablePIIIP3 Health Partners5007.18 million294.74 millionNot OptionableRNLXRenalytix10082.96 million63.06 millionOptionableSERASera Prognostics12037.67 million28.44 millionOptionableRNLX, SERA, PIII, and BDSX HeadlinesRecent News About These CompaniesAfter Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)May 29 at 10:36 AM | zacks.comSERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESMay 29 at 8:30 AM | prnewswire.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial ResultsMay 26 at 5:07 AM | finanznachrichten.deSERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCEMay 14, 2025 | prnewswire.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comDown -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a TurnaroundMay 13, 2025 | zacks.comWhat is William Blair's Forecast for SERA Q1 Earnings?May 13, 2025 | marketbeat.comSera Prognostics Inc (SERA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $15,552.56 in StockMay 10, 2025 | insidertrades.comSera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial OfficerMay 9, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics reports Q1 2025 earnings beatMay 9, 2025 | investing.comSera Prognostics Reports Q1 Revenues of $38K as Preterm Birth Test Commercialization ProgressesMay 9, 2025 | 360dx.comWhat I Wish I Knew: The Truth About Preterm Birth for Black WomenMay 9, 2025 | blackdoctor.orgSera Prognostics (SERA) Expected to Announce Earnings on WednesdayMay 9, 2025 | marketbeat.comSERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICERMay 8, 2025 | prnewswire.comInvesco Ltd. Sells 578,489 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)May 8, 2025 | marketbeat.comSera Prognostics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comSera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2025 | zacks.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSMay 7, 2025 | prnewswire.comShort Interest in Sera Prognostics, Inc. (NASDAQ:SERA) Drops By 18.2%May 4, 2025 | marketbeat.comSera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025April 24, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNLX, SERA, PIII, and BDSX Company DescriptionsBiodesix NASDAQ:BDSX$0.33 -0.02 (-5.16%) Closing price 04:00 PM EasternExtended Trading$0.32 0.00 (-0.15%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.P3 Health Partners NASDAQ:PIII$7.39 +0.00 (+0.05%) Closing price 03:58 PM EasternExtended Trading$7.40 +0.00 (+0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Renalytix NASDAQ:RNLXRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Sera Prognostics NASDAQ:SERA$1.64 -0.01 (-0.61%) Closing price 04:00 PM EasternExtended Trading$1.64 0.00 (0.00%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
